Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Tel Aviv - Delayed Quote ILA

Bonus BioGroup Ltd. (BONS.TA)

Compare
17.10
-0.50
(-2.84%)
At close: April 1 at 5:24:35 PM GMT+3
Loading Chart for BONS.TA
  • Previous Close 17.60
  • Open 17.70
  • Bid 17.10 x 100
  • Ask 17.30 x 624100
  • Day's Range 17.10 - 17.70
  • 52 Week Range 9.00 - 22.80
  • Volume 438,588
  • Avg. Volume 2,676,400
  • Market Cap (intraday) 199.716M
  • Beta (5Y Monthly) 1.05
  • PE Ratio (TTM) --
  • EPS (TTM) -0.06
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is based in Haifa, Israel.

bonus-bio.com

58

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BONS.TA

View More

Performance Overview: BONS.TA

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .

YTD Return

BONS.TA
43.70%
TA-125 (^TA125.TA)
1.47%

1-Year Return

BONS.TA
8.06%
TA-125 (^TA125.TA)
20.76%

3-Year Return

BONS.TA
71.07%
TA-125 (^TA125.TA)
17.42%

5-Year Return

BONS.TA
36.19%
TA-125 (^TA125.TA)
99.09%

Compare To: BONS.TA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BONS.TA

View More

Valuation Measures

Annual
As of 3/31/2025
  • Market Cap

    205.55M

  • Enterprise Value

    207.38M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    22.75

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -46.14%

  • Return on Equity (ttm)

    -129.44%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -29.47M

  • Diluted EPS (ttm)

    -0.06

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.73M

  • Total Debt/Equity (mrq)

    120.24%

  • Levered Free Cash Flow (ttm)

    -12.05M

Research Analysis: BONS.TA

View More

Company Insights: BONS.TA

Research Reports: BONS.TA

View More

People Also Watch